Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02935634 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
NCT02935634 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 190 participants.
The verdict
NCT02935634, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- DRUG Rucaparib
- BIOLOGICAL Relatlimab
- BIOLOGICAL BMS-986205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2022-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02935634
The ClinicalTrials.gov registry entry for NCT02935634 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nivolumab is the first listed.
NCT02935634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02935634 about?
NCT02935634 is a clinical study titled "A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer". The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.
What is the current status of trial NCT02935634?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2016-11-29. Estimated completion is 2022-05-11.
What interventions are being tested in trial NCT02935634?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Rucaparib (DRUG), Relatlimab (BIOLOGICAL), BMS-986205 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02935634?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.